newsfilter
← Latest News
Business Wire·

Virios Therapeutics' Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

-New Long-COVID Research Program Complements Fibromyalgia Phase 2b Clinical Research Program- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat deb